Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Accumulated Expenses (2016 - 2025)

iBio (IBIO) has disclosed Accumulated Expenses for 15 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 13.95% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 13.95% decrease, with the full-year FY2025 number at $1.3 million, down 33.68% from a year prior.
  • Accumulated Expenses was $1.6 million for Q4 2025 at iBio, up from $850000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.0 million in Q4 2022 to a low of $59000.0 in Q2 2022.
  • A 5-year average of $2.5 million and a median of $2.7 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 98.03% in 2022, then surged 6474.58% in 2023.
  • iBio's Accumulated Expenses stood at $2.8 million in 2021, then surged by 75.97% to $5.0 million in 2022, then dropped by 24.88% to $3.8 million in 2023, then tumbled by 51.16% to $1.8 million in 2024, then dropped by 13.95% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Accumulated Expenses are $1.6 million (Q4 2025), $850000.0 (Q3 2025), and $1.3 million (Q2 2025).